NGM Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 116345 min ago

@ $1.435

Wydano: 14 vas. 2024 @ 22:31

Zwrot: 7.32%

Poprzedni sygnał: vas. 14 - 16:52

Poprzedni sygnał: Sprzedaż

Zwrot: -3.68 %

Live Chart Being Loaded With Signals

Commentary (4 bal. 2024 @ 23:00):

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer...

Stats
Dzisiejszy wolumen	0.00
Średni wolumen	969 866
Kapitalizacja rynkowa	128.53M
EPS	$-0.330 ( 2024-05-02 )
Następna data zysków	( $0 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.890
ATR14	$0.00400 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Tcg Opportunity Iii Gp, Llc	Buy	1 000	Common Stock
2024-04-05	Tcg Opportunity Iii Gp, Llc	Sell	44 000	Common Stock
2024-04-05	Column Group Gp, Lp	Buy	1 000	Common Stock
2024-04-05	Column Group Gp, Lp	Sell	44 000	Common Stock
2024-04-05	Column Group L P	Buy	1 000	Common Stock

INSIDER POWER
-56.40
Last 100 transactions
Buy: 3 241 050 \| Sell: 9 885 031

Wolumen Korelacja

Długi: -0.36 (neutral)

Krótki: 0.00 (neutral)

Signal:(48.109) Neutral

NGM Biopharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
NVCN	0.959
TIOAU	0.946
AVEO	0.945
NTNX	0.944
ADTH	0.943
BNIXU	0.94
MSDA	0.939
ROVR	0.939
BUFF	0.938
NFLX	0.938

10 Najbardziej negatywne korelacje
AGFY	-0.958
ENNV	-0.956
IRBT	-0.954
KBNT	-0.948
CSSEP	-0.947
FWRD	-0.944
BIOL	-0.942
TCFC	-0.94
TBLT	-0.94
GOVX	-0.94

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NGM Biopharmaceuticals Korelacja - Waluta/Towar

-0.73
( moderate negative )

-0.75
( moderate negative )

0.00
( neutral )

0.47
( neutral )

NGM Biopharmaceuticals Finanse

Annual	2023
Przychody:	$4.42M
Zysk brutto:	$2.20M (49.72 %)
EPS:	$-1.730

FY	2023
Przychody:	$4.42M
Zysk brutto:	$2.20M (49.72 %)
EPS:	$-1.730

FY	2022
Przychody:	$55.33M
Zysk brutto:	$49.35M (89.19 %)
EPS:	$-1.990

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.555

Financial Reports:

No articles found.

NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.